Close Menu

Eli Lilly

The technology uses standard glass chips regionally photopatterned with discrete nanostructured separation materials to integrate all the steps of a given multistage assay. This enables higher throughput and better separation, according to one of its developers.

Advion is opening a new services facility in Indianapolis, and Eli Lilly will transition its drug discovery bioanalytical capability to the firm.

"With genomics, and pharmacogenomics, and all the other aspects of the cancers, we have to think of a different way than the randomized trial," said Patrick Loehrer, interim director of Indiana University's cancer center and a member of FDA's Oncology Drugs Advisory Committee.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

The chairman, CEO and founder of Alexandria Real Estate Equities told GenomeWeb Daily News that New York's academic and nonprofit research institutions will be among those who stand to benefit from the life sciences campus, the first phase of which it recently completed on Manhattan's East Side.

At a conference this week, an Eli Lilly official said that increasingly novel test platforms may pose challenges for drug developers in terms of regulatory approval and physician adoption.

Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.

Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.

The firms will use Molecular Templates' Direct Select Platform to create Engineered Toxin Bodies libraries that will be screened to identify potential drug candidates.

The study showed that alterations in the ABCB1 gene had no link to increased bleeding in patients treated with either Plavix or its competitor Effient, though patients treated with Plavix who were homozygous for a particular allele had an increased risk of cardiovascular death, heart attack, or stroke.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.